Dr. Chancellor is internationally recognized as the leader in urinary bladder treatment and research. Prior to joining Lipella, Dr. Chancellor was Professor of Urology at the University of Pittsburgh School of Medicine, and co-founder of Cook Myosite, originator of the first approved U.S. human urologic stem cell clinical trial. Dr. Chancellor has been principal investigator of over 75 additional clinical trials including physician sponsored IND trials. He is the recipient of over 25 NIH grants, and author of more than 300 peer-reviewed publications. He is consultant and advisory board member to over a dozen companies including Pfizer, Merck, J&J, Lilly, AstraZeneca, Allergan, Astellas, P&G and Indevus. Dr. Chancellor received his MD from the Medical College of Wisconsin, and completed his residency and fellowship training at the University of Michigan and Columbia University.
